// STATE LEGISLATION TRACKER

Arizona HB 2660 — health boards; licensure decisions; investigation

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Unknown

State: Arizona
Bill: HB 2660
Filed: 2026-01-20
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Based on the available title and metadata, HB2660 appears to address how Arizona health boards handle licensure decisions and investigations. It does not appear to directly regulate compounded peptides, off-label prescribing, telehealth, naturopathic or NP scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct peptide compounding impact is visible from the metadata
Peptide prescribers could be indirectly affected if board investigation rules change
No clear change to telehealth peptide prescribing is shown
No clear change to NP or naturopathic prescribing scope is shown
No controlled-substance or PDMP peptide issue is visible

What to Watch For

Note Watch whether the bill text changes board investigation timelines, standards, or appeal rights for clinicians.

Note Check whether medical, nursing, pharmacy, or naturopathic boards are specifically covered.

Concern If the bill makes investigations easier or discipline faster, peptide-focused clinicians could face more licensing risk.

Where the Bill Stands

The provided source says the OpenStates latest-action refetch failed, so the bill's current procedural status cannot be confirmed from the supplied metadata.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws